HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

vasectrin II (VS II)

analog of porcine secretin with sequence intermediate between secretin & vasoactive intestinal peptide (VIP); structure in first source
Also Known As:
VS II; 4-Ala-5-Val-secretin; secretin, Ala(4)-Val(5)-; secretin, alanyl(4)-valine(5)-; Secretin, 4-L-alanine-5-L-valine-
Networked: 194 relevant articles (6 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Hata, Mitsumasa: 3 articles (06/2011 - 08/2008)
2. Minami, Kazutomo: 3 articles (06/2011 - 08/2008)
3. Sezai, Akira: 3 articles (06/2011 - 08/2008)
4. Abdel-Rahman, Omar: 2 articles (01/2022 - 01/2018)
5. Ma, Rong: 2 articles (09/2020 - 01/2016)
6. Huang, Jin: 2 articles (01/2020 - 12/2011)
7. Peterlin, Borut: 2 articles (12/2018 - 12/2007)
8. Fan, Hong: 2 articles (01/2018 - 12/2011)
9. Liu, Ying: 2 articles (01/2018 - 10/2016)
10. Zhuo, Zhen-Jian: 2 articles (08/2017 - 02/2017)

Related Diseases

1. Neoplasms (Cancer)
2. Neoplasm Metastasis (Metastasis)
10/15/2022 - "However, in the multivariate analysis, only a lower NSTB score (0-1 vs 2; for OS, HR = 0.485, 95%CI: 0.251-0.940, P = 0.032; for DFS, HR = 0.453, 95%CI: 0.234-0.877, P = 0.019) and higher pathological grade, node and metastasis stage (0-I vs II-III; for OS, HR = 0.363, 95%CI: 0.158-0.837, P = 0.017; for DFS, HR = 0.342, 95%CI: 0.149-0.786, P = 0.012) were independent predictive factors. "
01/01/2021 - "Meta-analysis results showed that the expression of RUNX3 has significant differences in these comparisons: lymph node (LN) metastasis vs. non-LN metastasis (P = 0.26), EC tissues vs. normal tissues (P < 0.00001), clinical stages I/II vs. II/IV (P < 0.00001), muscular infiltration < 1/2 vs. muscular infiltration ≥ 1/2 (P < 0.00001), and G1 vs. G2/G3 (P < 0.00001). "
09/01/2004 - "Multivariate analyses identified an earlier primary tumor stage (I vs II) (P<.001), an absence of intervening stage III metastases (P =.02), solitary metastasis (P<.001), and a long (>36 months) disease-free interval from AJCC stage I or II to stage IV (P =.005) as predictive of survival. "
07/20/2019 - "Serum ENO1 was statistically significant (P < 0.05) in HCC tumor size (AUC = 0.663), tumor metastasis (AUC = 0.681), TNM stage (AUC = 0.710, stage I vs. II), and Edmondson grade (AUC = 0.685) (P < 0.05) and the elevated levels of ENO1 had significantly reduced (P < 0.05) the survival time. "
11/01/2006 - "HD was confirmed in 4 out of 6 cell lines and in 8 out of 34 (23.5%) RCC specimens, which correlated with the presence of metastasis, high tumor grade and had a tendency to more advanced stage (I vs. II-IV). "
3. Lymphoma (Lymphomas)
4. Tick Infestations
5. Tachycardia (Tachyarrhythmias)

Related Drugs and Biologics

1. Permethrin (Ambush)
2. Glucagon (Glukagon)
3. vasectrin I (VS I)
4. Proteins (Proteins, Gene)
5. vasectrin III
6. Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
7. Citric Acid (Citrate)
8. HLA-G Antigens (HLA G)
9. Cyclin D1
10. Lactic Acid (Lactate)

Related Therapies and Procedures

1. Therapeutics
2. Spinal Cord Stimulation
3. Lymph Node Excision (Lymph Node Dissection)
4. Limb Salvage
5. Radiotherapy